Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Clinical advances in hematology & oncology : H&O

• Publication date

  2016-11-01

• Fields of study

  Medicine

• Identifiers
  PMID 27930644
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase Ib trial of atezolizumab in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer (mTNBC).

  2016cited by this paper
• Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer.

  2016cited by this paper
• Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer.

  2016cited by this paper
• PD-1 Blockade Boosts Radiofrequency Ablation–Elicited Adaptive Immune Responses against Tumor

  2016cited by this paper
• Mutations as munitions: Neoantigen vaccines get a closer look as cancer treatment

  2016cited by this paper
• Phase II Study of Autologous Monocyte-Derived mRNA Electroporated Dendritic Cells (TriMixDC-MEL) Plus Ipilimumab in Patients With Pretreated Advanced Melanoma.

  2016cited by this paper
• Targeting the programmed cell death-1 pathway in breast and ovarian cancer

  2016cited by this paper
• A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors.

  2016cited by this paper
• Abstract S5-07: Preliminary efficacy and safety of pembrolizumab (MK-3475) in patients with PD-L1–positive, estrogen receptor-positive (ER+)/HER2-negative advanced breast cancer enrolled in KEYNOTE-028

  2016cited by this paper
• Cancer Immunology: Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

  2016cited by this paper
• Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

  2016cited by this paper
• Nivolumab in previously untreated melanoma without BRAF mutation.

  2015cited by this paper
• Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.

  2015cited by this paper
• Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer

  2015cited by this paper
• Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.

  2015cited by this paper
• Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

  2015cited by this paper
• The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

  2015cited by this paper
• Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer

  2015cited by this paper
• Pembrolizumab for the treatment of non-small-cell lung cancer.

  2015cited by this paper
• Interferon-γ-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression

  2015cited by this paper
• Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer: A Randomized Clinical Trial.

  2015cited by this paper
• Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.

  2015cited by this paper
• Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.

  2015cited by this paper
• Pembrolizumab versus Ipilimumab in Advanced Melanoma.

  2015cited by this paper
• Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.

  2015cited by this paper
• Tumor immune remodeling by TGFβ inhibition improves the efficacy of radiation therapy

  2015cited by this paper
• Tumor immunology and cancer immunotherapy: summary of the 2014 SITC primer

  2015cited by this paper
• Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)

  2015cited by this paper
• Expression of PDL1 (B7-H1) before and after neoadjuvant chemotherapy (NAC) in urothelial carcinoma.

  2015cited by this paper
• New peptide vaccine for HER2-expressing breast tumors.

  2015cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• TGFβ Inhibition Prior to Hypofractionated Radiation Enhances Efficacy in Preclinical Models

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199.

  2014cited by this paper
• Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.

  2014cited by this paper
• Peptide-Based Vaccination and Induction of CD8+ T-Cell Responses Against Tumor Antigens in Breast Cancer

  2014cited by this paper
• Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity.

  2014cited by this paper
• Genetic basis for clinical response to CTLA-4 blockade in melanoma.

  2014cited by this paper
• Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

  2014cited by this paper
• Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer

  2014cited by this paper
• PD-L1 Expression in Triple-Negative Breast Cancer

  2014cited by this paper
• Emerging immunotherapy strategies in breast cancer.

  2014cited by this paper
• Nivolumab plus ipilimumab in advanced melanoma.

  2013cited by this paper
• Tremelimumab: a review of development to date in solid tumors.

  2013cited by this paper
• Concurrent Radiotherapy and Ipilimumab Immunotherapy for Patients with Melanoma

  2013cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial.

  2013cited by this paper
• OX40 is a potent immune-stimulating target in late-stage cancer patients.

  2013cited by this paper
• Key roles of adjuvants in modern vaccines

  2013cited by this paper
• A pilot study of preoperative (Pre-op), single-dose ipilimumab (Ipi) and/or cryoablation (Cryo) in women (pts) with early-stage/resectable breast cancer (ESBC).

  2013cited by this paper
• Abstract S1-06: Increased tumor-associated lymphocytes predict benefit from addition of carboplatin to neoadjuvant therapy for triple-negative and HER2-positive early breast cancer in the GeparSixto trial (GBG 66)

  2013cited by this paper
• Response to HER-2 Pulsed DC1 Vaccines is Predicted by Both HER-2 and Estrogen Receptor Expression in DCIS

  2013cited by this paper
• Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study.

  2013cited by this paper
• Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.

  2012cited by this paper
• HER‐2 pulsed dendritic cell vaccine can eliminate HER‐2 expression and impact ductal carcinoma in situ

  2012cited by this paper
• Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

  2012cited by this paper
• Management of immune-related adverse events and kinetics of response with ipilimumab.

  2012cited by this paper
• Topical TLR7 Agonist Imiquimod Can Induce Immune-Mediated Rejection of Skin Metastases in Patients with Breast Cancer

  2012cited by this paper
• Modulation of GITR for cancer immunotherapy.

  2012cited by this paper
• Immunologic correlates of the abscopal effect in a patient with melanoma.

  2012cited by this paper
• Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity.

  2012cited by this paper
• Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

  2012cited by this paper
• Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study

  2012cited by this paper
• Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer.

  2011cited by this paper
• Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

  2011cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010cited by this paper
• Tremelimumab in Combination with Exemestane in Patients with Advanced Breast Cancer and Treatment-Associated Modulation of Inducible Costimulator Expression on Patient T Cells

  2010cited by this paper
• Sipuleucel-T immunotherapy for castration-resistant prostate cancer.

  2010cited by this paper
• Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses.

  2009cited by this paper
• Sialyl-Tn vaccine induces antibody-mediated tumour protection in a relevant murine model

  2009cited by this paper
• PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer

  2009cited by this paper
• The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02

  2009cited by this paper
• Immunological aspects of cancer chemotherapy

  2008cited by this paper
• Cooperation between CD4+ and CD8+ T cells: when, where, and how.

  2006cited by this paper
• Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer.

  2005cited by this paper
• Enhancement of Antitumor Immunity by CTLA-4 Blockade

  1996cited by this paper
• Immunological Aspects of Cancer Chemotherapy

  1980cited by this paper

• Aquilaria Crassna Pierre Ex Lecomte Leaf Extract Induces Apoptosis and Immunogenic Cell Death in Breast Cancer Cells, Enhancing Anti-Tumor Effects of Dendritic Cells

  2025cites this paper
• CRISPR/Cas9-mediated knockout strategies for enhancing immunotherapy in breast cancer

  2024cites this paper
• Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment.

  2024cites this paper
• An angiogenesis-associated gene-based signature predicting prognosis and immunotherapy efficacy of head and neck squamous cell carcinoma patients

  2024cites this paper
• A novel model associated with tumor microenvironment on predicting prognosis and immunotherapy in triple negative breast cancer

  2023cites this paper
• A narrative review for radiation oncologists to implement preoperative partial breast irradiation

  2023cites this paper
• Panobinostat Induced Spatial In Situ Biomarkers Predictive of Anti-PD-1 Efficacy in Mouse Mammary Carcinoma

  2023cites this paper
• Multi-catheter interstitial brachytherapy for an advanced breast cancer patient with multiple complications: A case report

  2022cites this paper
• Identification of glycogene signature as a tool to predict the clinical outcome and immunotherapy response in breast cancer

  2022cites this paper
• Identification of Immune Cell Components in Breast Tissues by a Multiparametric Flow Cytometry Approach

  2022cites this paper
• The performance and perspectives of dendritic cell vaccines modified by immune checkpoint inhibitors or stimulants.

  2022cites this paper
• Activation of cytotoxic T lymphocytes by self-differentiated myeloid-derived dendritic cells for killing breast cancer cells expressing folate receptor alpha protein

  2022cites this paper
• Investigating the Potential of Isolating and Expanding Tumour-Infiltrating Lymphocytes from Adult Sarcoma

  2022cites this paper
• The Expression of Immune Checkpoint Inhibitors PDL-1 and CTLA-4 in Pancreatic Versus Non-Pancreatic Periampullary Adenocarcinoma: An Immunohistochemical Study

  2021influential citation
• Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer

  2021cites this paper
• TumorSelect® Technology Enhancing the Safety and Efficacy of Cancer Chemotherapy

  2021cites this paper
• Induction of Triple-negative Breast Cancer Cells to Immunogenic Cell Death and Increase Cross-Presentation by Streptomyces sanyensis

  2021cites this paper
• Exploration of therapeutic applicability and different signaling mechanism of various phytopharmacological agents for treatment of breast cancer.

  2021cites this paper
• Role of betulinic acid derivative SH-479 in triple negative breast cancer and bone microenvironment

  2021cites this paper
• Immune-related biomarkers in triple-negative breast cancer

  2021cites this paper
• Clinical Data on Immunotherapy in Breast Cancer

  2020cites this paper
• Prospective, randomized, single-blinded, multi-center phase II trial of two HER2 peptide vaccines, GP2 and AE37, in breast cancer patients to prevent recurrence

  2020cites this paper
• The efficacy and safety of combined immune checkpoint inhibitors (nivolumab plus ipilimumab): a systematic review and meta-analysis

  2020cites this paper
• Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy

  2020cites this paper
• Investigating stromal gene expression in metastatic and non-metastatic canine mammary tumours

  2019cites this paper
• Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.

  2019cites this paper
• Other Systemic Treatments for Breast Cancer

  2019cites this paper
• A Novel Method for Controlled Gene Expression via Combined Bleomycin and Plasmid DNA Electrotransfer

  2019cites this paper
• Aberrant Expression of N-Glycolyl GM3 Ganglioside Correlates with Nuclear Grade in Stage II/III Resectable Estrogen and Progesterone Receptors Positive Breast Cancer

  2019cites this paper
• Intradermal DNA vaccination combined with dual CTLA-4 and PD-1 blockade provides robust tumor immunity in murine melanoma

  2019cites this paper
• Targeting the Interplay between Epithelial-to-Mesenchymal-Transition and the Immune System for Effective Immunotherapy

  2019cites this paper
• Vaccine Therapies for Breast Cancer.

  2019cites this paper
• Immunotherapy in hepatocellular carcinoma.

  2019cites this paper
• The Impact of microRNAs in Breast Cancer Angiogenesis and Progression.

  2019cites this paper
• Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas

  2018cites this paper
• Inhibition of RON kinase potentiates anti-CTLA-4 immunotherapy to shrink breast tumors and prevent metastatic outgrowth

  2018cites this paper
• Delivering all in one: Antigen‐nanocapsule loaded with dual adjuvant yields superadditive effects by DC‐directed T cell stimulation

  2018cites this paper
• Triple negative breast cancer: Emerging therapeutic modalities and novel combination therapies.

  2018cites this paper
• Invasive lobular and ductal breast carcinoma differ in immune response, protein translation efficiency and metabolism

  2018cites this paper
• Organ‐on‐a‐Chip Systems for Women's Health Applications

  2018cites this paper
• Emerging ways to treat breast cancer: will promises be met?

  2018cites this paper
• Ki67 and lymphocytes in the pretherapeutic core biopsy of primary invasive breast cancer: positive markers of therapy response prediction and superior survival

  2017cites this paper
• Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.

  2017cites this paper
• Invasive Breast Cancer Therapy 2017: How Well Are We Hitting the Target?

  2017cites this paper
• Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer

  2017cites this paper
• Zielgerichtete Therapie des HER2-positiven metastasierten Mammakarzinoms

  2016cites this paper